<DOC>
	<DOCNO>NCT01658956</DOCNO>
	<brief_summary>The study aim confirm reduce dosage GCSF effective prevent febrile neutropenia among patient breast cancer , treat chemotherapy present low moderate risk develop febrile neutropenia .</brief_summary>
	<brief_title>Effectiveness Reduced GCSF Dosing Patients With Low Moderate Risk Febrile Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Breast cancer Chemotherapy administration ( new line ) Chemotherapy type : FEC , EC , AC , docetaxel contain regimen Chemotherapy setting : adjuvant neoadjuvant Eligibility receive reimburse GCSF</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>GCSF</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>